iwMDS 2022

24–26 June 2022 | Miami, FL, USA

iwMDS 2022

24–26 June 2022 | Miami, FL, USA

VJHemOnc is pleased to be the official media partner for the 1st International Workshop on Myelodysplastic Syndromes (iwMDS), which was held in Miami, FL, on 24-26 June 2022.

The workshop brought together leading international clinicians and researchers in an in-person forum to discuss the current status and recent advances in MDS with the aim to optimize clinical care.

Morphologic classification of MDS, defining the boundary between MDS and other myeloid neoplasms

John Bennett
Morphologic Classification of MDS focus on dysplasia and blasts
John Bennett University of Rochester Medical Center, Rochester, NY, United States
Sanam Loghavi
Morphologic correlates of cytogenetic and molecular alterations in MPNs
Sanam Loghavi MD Anderson Cancer Center, Houston, TX, United States
Robert Hasserjian
Defining the boundary between MDS and other MPNs
Robert Hasserjian Massachusetts General Hospital, Boston, MA, United States
Mina Xu
Non-neoplastic morphologic mimics of myelodysplastic syndromes
Mina Xu New Haven, CT, United States
Q&A discussion: MDS Morphology
John Bennett, Sanam Loghavi, Robert Hasserjian, Mina Xu

How can we improve efficiency of drug approval? – Part I

Kelly Norsworthy
The FDA’s perspective on new therapy development for MDS
Kelly Norsworthy Johns Hopkins Medicine, Baltimore, MD, United States
Guillermo Sanz
European & global regulatory harmonization efforts
Guillermo Sanz La Fe University Hospital, Valencia, Spain
Mikkael  Sekeres
Meaningful clinical benefit and totality of data
Mikkael Sekeres Sylvester Comprehensive Cancer Center, Miami, FL, United States
Amer Zeidan
Academic perspective: What should approval endpoints be?
Amer Zeidan Yale University School of Medicine and Yale Cancer Center, New Haven, CT, United States

How can we improve efficiency of drug approval? – Part II

Olatoyosi Odenike
An overview of MDS MyeloMATCH efforts
Olatoyosi Odenike Duchossois Center for Advanced Medicine, Chicago, IL, United States
Richard  Little
Biomarker-driven clinical trials & early endpoints in NCI - MyeloMATCH
Richard Little National Cancer Institute, Rockville, MD, United States
Andrew Wei
BCL2 modulation in MDS
Andrew Wei Alfred Hospital and Monash University, Melbourne, Australia
Guillermo  Garcia-Manero
Role of oral HMAs in MDS
Guillermo Garcia-Manero University of Texas MD Anderson Cancer Center, Houston, TX, United States

How can we improve efficiency of drug approval? – Part III

Valeria  Santini
Imetelstat and HIF inhibitors evolving use in MDS
Valeria Santini University of Florence, Florence, Italy
Andrew Brunner
Is there still a way forward for APR-246 in TP53-mutated MDS?
Andrew Brunner Massachusetts General Hospital, Boston, MA, United States
Hetty Carraway
Updates on SY-1425
Hetty Carraway Cleveland Clinic, Cleveland, OH, United States
Justin Taylor
XPO1 therapeutic manipulation in MDS
Justin Taylor Sylvester Comprehensive Cancer Center, Miami, FL, United States
Roundtable Discussion: How can we improve efficiency of drug approval?
Hetty Carraway, Olatoyosi Odenike, Andrew Brunner, Justin Taylor

Inflammation, immune dysregulation and targeting in MDS – Part I

Vijay Kuchroo
The role of TIM-3 in pathogenesis of MDS
Vijay Kuchroo Brigham and Women's Hospital, Boston, MA, United States
David Sallman
CD47 pathway and its therapeutic targeting
David Sallman H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Tae Kon Kim
Targeting LAIR and PD-1H (VISTA) in MDS/AML
Tae Kon Kim Vanderbilt University, Nashville, TN, United States

Inflammation, immune dysregulation and targeting in MDS – Part II

Amer Zeidan
PD1/PDL-1/CTLA-4, and TIM-3 targeting in MDS
Amer Zeidan Yale University School of Medicine and Yale Cancer Center, New Haven, CT, United States
Uwe Platzbecker
IRAK inhibitors in MDS and AML
Uwe Platzbecker University Hospital in Leipzig, Leipzig, Germany
Gail Roboz
CAR T-cell therapy in MDS and AML
Gail Roboz Weill Medical College of Cornell University, New York City, NY, United States
Naval Daver
NK therapeutic modulation for MDS and AML
Naval Daver University of Texas MD Anderson Cancer Center, Houston, TX, United States
Alan List
Targeting the NLRP3 inflammasome in MDS
Alan List Precision BioSciences, Durham, NC, United States
Roundtable Discussion: Inflammation, immune dysregulation and targeting in MDS
Uwe Platzbecker, Alan List, David Sallman, Daniel Starczynowski

Updates in classification and risk stratification

Robert Hasserjian
MDS classification updates
Robert Hasserjian Massachusetts General Hospital, Boston, MA, United States
Rafael  Bejar
The IPSS-Molecular
Rafael Bejar University of California, San Diego, CA, United States
Matteo Della Porta
The EuroMDS Molecular Prognostic Tool
Matteo Della Porta Humanitas Research Hospital, Milan, Italy
Aziz Nazha
The MDS Clinical Research Consortium Molecular Prognostic Tool
Aziz Nazha Cleveland Clinic, Cleveland, OH, United States
Jane  Churpek
Genetic predisposition to MDS
Jane Churpek University of Wisconsin Carbone Cancer Center, Madison, WI, United States
Roundtable Discussion: Updates in classification and risk stratification in MDS
Rafael Bejar, Aziz Nazha, Robert Hasserjian, Jane Churpek

Clonal hematopoiesis and Pre-MDS states

Zhuoer Xie
Understanding approach to risk of hematologic malignancies in CH
Zhuoer Xie Rochester, MN, United States
Mrinal Patnaik
Linking CH to progression of disease
Mrinal Patnaik Rochester, MN, United States
Eric Padron
Could we prevent therapy-related myeloid malignancies?
Eric Padron Moffitt Cancer Center, Tampa, FL, United States
Roundtable discussion: Clonal hematopoiesis and pre-MDS states
Eric Padron, Mrinal Patnaik, Zhuoer Xie

Splicing factors and RNA pathobiology/epigenetics

Stephanie Halene
An update on MDS animal models
Stephanie Halene Yale School of Medicine, New Haven, CT, United States

Non-interventional and big data research in MDS

Aziz Nazha
Artificial intelligence in MDS
Aziz Nazha Cleveland Clinic, Cleveland, OH, United States
Amy DeZern
NHLBI natural history registry for MDS
Amy DeZern Johns Hopkins University School of Medicine, Baltimore, MD, United States
Fabio Efficace
Patient-reported outcomes and quality-of-life instruments in MDS
Fabio Efficace Feinberg School of Medicine, Chicago, IL, United States
Rena Buckstein
Incorporating patient-related factor risk stratification in clinical trials
Rena Buckstein Sunnybrook Health Sciences Centre

Key highlights from iwMDS 2022

Roundtable discussion: Key highlights from iwMDS 2022
Amer Zeidan, Rena Buckstein, Valeria Santini

iwMDS 2022 has been supported by:


Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter